Prakt. lékáren. 2016; 12(6): 232-235 | DOI: 10.36290/lek.2016.056

Pyridoxine use in children with epilepsy: a pharmacist’s point of view

Petra Thomson1,2, Kateřina Ládová1,3
1 Katedra sociální a klinické farmacie, Farmaceutická fakulta v Hradci Králové, Univerzita Karlova
2 Nemocniční lékárna, Fakultní nemocnice Hradec Králové
3 Oddělení klinické farmacie, Nemocnice Na Homolce, Praha

Vitamin B6 (pyridoxine) plays a pivotal role in development and functioning of central nervous system. As with other vitamins of

the B group, pyridoxine deficiency is rare, but it may occur as a result of some specific genetic disorders of metabolism. This may

lead into functional deficiency of vitamin B6 and devolve into pyridoxine-dependent epilepsy in children. Pyridoxin dosing in this

indication is based strictly on individual patient’s response and when reeded doses as high as 1g daily are administered orally.

Especially with high dose pyridoxine regimens in paediatric population, it is preferable to avoid crushing tablets for administration

and choose a suitable concentration of extemporaneously prepared oral liquid forms. In some types of neonatal and infantile

seazures, therapeutic trial with pyridoxal-5’-phosphate is more appropriate choice yielding more successful results.

Keywords: vitamin B6, pyridoxine hydrochloride, pyridoxal-5-phosphate, epilepsy, neonatal seizures, extemporaneous preparation

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Thomson P, Ládová K. Pyridoxine use in children with epilepsy: a pharmacist’s point of view. Praktické lékárenství. 2016;12(6):232-235. doi: 10.36290/lek.2016.056.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McCormick D. Vitamin B6. In: Bowman B, Russell R, eds. Present Knowledge in Nutrition. 9th ed. Washington, DC: International Life Sciences Institute; 2006: 187 p.
    2. Vitamin B6, dietary supplement factsheet. [on line]. National Institutes of Health, Office of Dietary Supplements, 2016. [cit. 2016-09-11]. URL: https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/#h2.
    3. Johnson LE: Vitamin B6 (pyridoxine). [on line]. Merck Manual Professional version, Sep 2016. [cit. 2016-10-11]. URL: http://www.merckmanuals.com/professional/nutritional-disorders/vitamin-deficiency,-dependency,-and-toxicity/vitamin-b-6.
    4. Vitamin B6 (pyridoxine): Pediatric drug information, Topic 12753 Version 85.0. [on line]. UpToDate, Inc, c2016. [cit. 2016-08-28]. URL: http://www.uptodate.-com.ezproxy.is.cuni.cz/contents/vitamin-b6-pyridoxine-pediatric-drug-information?source=search_result&search=pyridoxine&selectedTitle=2%7E150
    5. Souhrn údajů o přípravku Pyridoxin Léčiva, revize textu 23/02/2012. [on line]. SÚKL. [cit. 2016-08-29]. URL: http://www.sukl.cz/modules/medication/search.php
    6. Pyridoxal-5-Phosphate a Pyridoxine monografie, revize textu 20/11/2015. [on line]. Evelina London Paediatric Formulary. [cit. 2016-08-28]. URL: http://cms.ubqo.com/public/d2595446-ce3c-47ff-9dcc-63167d9f4b80.
    7. Pyridoxine hydrochloride (Vitamin B6). [on line]. British National Formulary for Children August 2016 via MedicinesComplete. [cit. 2016-08-28]. URL: www. medicinescomplete.com
    8. Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 2002; 26: 181-185. Go to original source...
    9. Mills PB, Struys E, Jakobs C, et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat Med 2006; 12(3): 307-309. Go to original source... Go to PubMed...
    10. Gouti?res F, Aicardi J. Atypical presentations of pyridoxine-dependent seizures: a treatable cause of intractable epilepsy in infants. Ann Neur ol 1985; 17(2): 117-120. Go to original source... Go to PubMed...
    11. Pearl PL. Amenable Treatable Severe Pediatric Epilepsies. Semin Pediatr Neurol 2016; 23(2): 158-166. Go to original source...
    12. Papetti L, Parisi P, Leuzzi V, et al. Metabolic epilepsy: an update. Brain Dev 2013; 35(9): 827-841. Go to original source...
    13. Souhrn údajů o přípravku Pyridoxin Léčiva inj., revize textu 21/11/2015. [on line]. SÚKL. [cit. 2016-08-28]. URL: http://www.sukl.cz/modules/medications/search.php.
    14. Wang H, Kuo M, Chou M, et al. Pyridoxal phosphate is better than pyridoxine for controlling idiopathic intractable epilepsy. Archives of Disease in Childhood. 2005; 90(5): 512-515. Go to original source... Go to PubMed...
    15. Klovrzová S, Horák P, a kol. Pyridoxin. In: Individuálně připravovaná léčiva pro pediatrii. Praha: Galén, 2013: 103 s.
    16. Zákon MZ ČR č. 378/2007 Sb., o léčivech [on line]. c2016 [cit. 2016-03-20]. URL: https://portal.gov.cz/app/zakony/zakonPar.jsp?idBiblio=65289&nr=378~2F2007&rpp=15#local-content.
    17. Rote Liste 2016, Vitamin B6 (Pyridoxin) článek 84011-84016, Frankfurt/Main: Herausgeber und Verlag 2016, 56. Ausgabe: 1984 s.
    18. Leganés-Ramos A, Álvaro-Alonso EA, Martín de Rosales-Cabrera AM, Pérez-Encinas M. Oral formulation of pyridoxine for the treatment of pyridoxinedependent epilepsy in a paediatric patient. Farm Hosp 2016; 40(2): 131-133. Go to PubMed...
    19. Nahata MC, Pai VB, Hipple TF. Pediatric Drug Formulations, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004: 307 p.
    20. Syrspend(R) SF Pr?ehled kompatibilni?ch la?tek, Pyridoxin HCL. [on line]. Fagron. [cit. 2016-08-28]. URL: https://shop.fagron.cz/shared/files_fagroncz/documents/kompatibility.pdf
    21. MV-AISLP pro Windows, verze 4.2016.
    22. Committee for Medicinal products for Human (CHMP): Reflection paper: Formulations of choice for the paediatric population. [on line]. EMEA; London 2006. [cit. 2016-08-28]. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.